The pathological and biological nature of screen-detected breast carcinomas: A morphological and immunohistochemical study

Journal of Pathology

Volumn 182, Issue 1, 1997, Pages 29-35

  Cowan, William K ^a,b   Kelly, Peter ^c   Sawan, Ali ^b   Cunliffe, William J ^a   Henry, Linda ^b   Higgs, Michael J ^a   Lunt, Linsley G ^a   Young, James R ^a   Horne, Charles H W ^b   Angus, Brian ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c TEESSIDE UNIVERSITY   (United Kingdom)

Author keywords

breast carcinoma; c erb B 2; cathepsin D; epidermal growth factor receptor; oestrogen receptor; oncogenes; oncosuppressor genes; p53; progesterone receptor; prognosis; Rb; screening

Indexed keywords

CATHEPSIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER SCREENING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0031004823     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9896(199705)182:1<29::aid-path820>3.0.co;2-%23     Document Type: Article

References (54)

1. Nicholson S, Webb AJ, Coghlan B, Farndon JR, Armstrong JS, Davies JD. Will screening for breast cancer reduce mortality? Evidence from the first year of screening in Avon. Ann R Coll Surg Engl 1993; 75: 8-12.
2. Boulter PS. Invited comment. Ann R Coll Surg Engl 1993; 75: 12.
3. Klemi PJ, Joensuu H, Toikkanen S, et al. Aggressiveness of breast cancers found with and without screening. Br Med J 1992; 304: 467-469.
4. Holmberg L, Ekbom A, Zack M. Do screening-detected invasive breast cancers have a natural history of their own? Eur J Cancer 1992; 28A: 920-923.
5. Rajakariar R, Walker RA. Pathological and biological features of mammographically detected invasive breast carcinomas. Br J Cancer 1995; 71: 150-154.
6. Tabar L, Fagerberg G, Day NE, Duffy SW, Kitchin RM. Breast cancer treatment and natural history: new insights from results of screening. Lancet 1992; 339: 412-414.
7. Lewis S, Locker A, Todd JH, et al. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 1990; 43: 385-389.
8. Nicholson S, Sainsbury JRC, Halcrow P, et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991; 63: 146-150.
9. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087-2090.
10. Dykins R, Corbett IP, Henry JA, et al. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 1991; 163: 105-110.
11. Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63: 439-443.
12. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206.
13. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-855.
14. Sawan A, Randall B, Angus B, et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 1992; 168: 23-28.
15. Varley JM, Armour J, Swallow JE, et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene 1989; 4: 725-729.
16. Williams MR, Todd JH, Ellis IO, et al. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer 1987; 55: 67-73.
17. Winstanley J, Cook T, George WD, et al. The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast. Br J Cancer 1991; 64: 99-101.
18. Tinnemans JGM, Beex LVAM, Wobbes Th, Sluis RF, Raemaekers JMM, Benraad Th. Steroid-hormone receptors in nonplalpable and more advanced stages of breast cancer. Cancer 1990; 66: 1165-1167.
19. Henry JA, McCarthy AL, Angus B, et al. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. Cancer 1990; 65: 265-271.
20. Royal College of Pathologists Working Group. Pathology reporting in breast cancer screening. J Clin Pathol 1991; 44: 710-725.
21. Anonymous. Screening for breast cancer: examination and reporting of histopathological preparations. Lancet 1988; 2: 953.
22. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL. Anderson TJ, eds. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987; 300-311.
23. Henry L, Angus B, Lennard TWJ, et al. New monoclonal antibodies to oestrogen and progesterone receptor: characterisation and clinical studies in human breast cancer. J Pathol 1993; 169: 168A.
24. Waterfield MD. Epidermal growth factor and related molecules. Lancet 1989; 2: 1243-1246.
25. Stefanini M, de Martino C, Zamboni L. Fixation of ejaculated spermatozoa for electron microscopy, Nature 1967; 216: 173-174.
26. Barnes DM, Millis RR. Oestrogen receptors: the history, the relevance and the method of evaluation. In: Kirkham B, Lemoine NR, eds. Progress in Pathology, Vol. 2. Edinburgh: Churchill Livingstone, 1995; 89-114.
27. Kinsel LB, Szabo E, Greene GL, et al. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989; 49: 1052-1056.
28. Cowan WK, Angus B, Henry J, et al. Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. Br J Cancer 1991; 64: 780-784.
29. STATA Release 3 Reference Manual. 5th edn. Santa Monica, CA: Computing Resource Centre, 1992.
30. Cowan WK. Observations on the pathology of screen-detected mammary carcinoma. PhD Thesis, University of Newcastle upon Tyne, 1994.
31. Ellis IO, Galea MH, Locker A, et al. Early experience in breast cancer screening: emphasis on development of protocols for triple assessment. Breast 1993; 2: 148-153.
32. Anderson TS, Lamb J, Alexander F, et al. Comparative pathology of prevalent and incident cancers detected by breast screening. Lancet 1986; 1: 519-523.
33. Anderson TJ, Lamb J, Donnan P, et al. Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer 1991; 64: 108-113.
34. Chaudary MA, Millis RR, Hoskins EOL, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 1984; 71: 711-714.
35. Gibbs NM. Comparative study of the histopathology of breast cancer in a screened and unscreened population investigated by mammography. Histopathology 1985; 9: 1307-1318.
36. Duffy SW, Tabar L, Fagerberg G, et al. Breast screening, prognostic factors and survival - results from the Swedish two county study. Br J Cancer 1991; 64: 1133-1138.
37. Rodin AE, Larson DL, Roberts DK. Nature of the perineural space invaded by prostatic carcinoma. Cancer 1967; 20: 1772-1779.
38. Russo J, Fredrick J, Ownby HE, et al. Predictors of recurrence and survival of patients with breast cancer. Cancer 1987; 88: 123-131.
39. Winstanley JHR, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM, Rudland PS. Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer 1993; 67: 767-772.
40. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
41. Davidoff AM, Kerns B-JM, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progession. Cancer Res 1991; 51: 2605-2610.
42. Soomro S, Shousha S, Sinnett HD. Oestrogen and progesterone receptors in screen-detected breast carcinoma: an immunohistological study using paraffin sections. Histopathology 1992; 21: 543-547.
43. Nicholson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node-negative subgroup. Br J Cancer 1991; 63: 146-150.
44. O'Reilly SM, Barnes DM, Camplejohn RS, et al. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 1991; 63: 441-446.
45. Winstanley J, Cook T, George WD, et al. The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast. Br J Cancer 1991; 64: 99-101.
46. Charpin C, Devictor B, Bonnier P, et al. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Pathol 1993; 170: 463-470.
47. Elledge RM, Fuqua SAW, Clark GM, et al. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993; 26: 225-235.
48. Martinazzi M, Crivelli F, Zampatti C, et al. Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol 1993; 100: 213-217.
49. Page DL, Dupont WD, Rogers LW, et al. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer 1982; 49: 751-758.
50. Thomas DB, Whitehead J, Dorse C, et al. Mammographic calcifications and risk of subsequent breast cancer. J Natl Cancer Inst 1993; 85: 230-235.
51. Tabar L, Duffy SW, Krusemo UB. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol 1987; 23: 959-962.
52. Linell F, Ljungberg O, Andersson I. Breast carcinoma: aspects of early stages, progression and related problems. Acta Pathol Microbiol Scand (A) 1980; 272: 1-233.
53. Tubiana M, Koscielny S. Natural history of human breast cancer: recent data and clinical implications. Breast Cancer Res Treat 1991; 18: 125-140.
54. Moezzi M, Melamed J, Vamvakas et al. Morphological and biological characteristics of mammogram-detected invasive breast cancer. Hum Pathol 1996; 27: 944-948.